A prospective, crossover randomized trial of the optimal timing for leucovorin rescue after high-dose methotrexate management in adult non-Hodgkin's lymphoma patients
- 2 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 61 (8), 1842-1849
- https://doi.org/10.1080/10428194.2020.1747061
Abstract
This study aimed to investigate the optimal time of leucovorin rescue for HDMTX in non-Hodgkin's lymphoma (NHL) patients. Ninety-eight patients treated with HDMTX were randomly assigned to receive leucovorin at either 18 or 24 h after initiation of HDMTX infusion during the first cycle and switched to the other mode in the second cycle. All courses achieved an efficacious MTX concentration. Compared to the 18th hour group, the 24th hour group exhibited an increase in incidence of thrombocytopenia (48% versus 34.7%, p = .036) and grade III/IV neutropenia (34.7% versus 21.4%, p = .039). No bleeding occurred and the incidence of fever with grade III/IV neutropenia was low with no difference observed between the two groups. We recommend that with the HDMTX generally used most adult patients with NHL may have greater therapeutic benefit and acceptable toxicity with their LV rescue started at 24 h instead of 18 h.This publication has 32 references indexed in Scilit:
- High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patientsBritish Journal of Clinical Pharmacology, 2011
- Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value ?Journal of Clinical Pharmacy & Therapeutics, 2010
- Advances in individual prediction of methotrexate toxicity: a reviewBritish Journal of Haematology, 2009
- High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemiaLeukemia, 2006
- High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: “Folate Overrescue” Concept RevisitedClinical Chemistry, 2006
- Methotrexate levels and outcome in osteosarcomaPediatric Blood & Cancer, 2005
- High dose methotrexate in adult patients with osteosarcoma: Clinical and pharmacokinetic resultsActa Oncologica, 2005
- Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcomeJournal of Neurosurgery, 1994
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)The New England Journal of Medicine, 1948